By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Molecular Templates Inc. 

610 University Avenue
Room 7-117
Toronto  Ontario  M5G 2M9  Canada
Phone: 416-946-2875 Fax: 416-946-6529



Company News
Takeda (TKPYY) And Molecular Templates Announce Multi-Target Research And Licensing Collaboration To Develop Next-Generation Oncology Therapies 8/3/2017 12:00:45 PM
Molecular Templates Completes Merger With Threshold (THLD) And Private Placements 8/2/2017 10:15:24 AM
Crippled Bay Area Pharma Threshold (THLD) Rockets on Reverse Merger Deal With Molecular Templates 3/17/2017 5:52:51 AM
Molecular Templates Inc. To Present Clinical And Preclinical Data For MT-3724 And Next Generation Engineered Toxin Bodies (ETBS) At The 2016 AACR Annual Meeting 4/6/2016 10:23:48 AM
Molecular Templates Inc. Presents Preclinical Data On De-Immunized Engineered Toxin Bodies (ETB) With Novel Immuno-Oncology Capabilities At The 2015 American Association for Cancer Research Annual Meeting 4/16/2015 12:56:59 PM
Molecular Templates Inc. Announces Start Of Phase 1 Clinical Trial Of MT-3724 In Refractory Non-Hodgkin’s Lymphoma 3/5/2015 10:06:12 AM
Veristat, Inc. And Molecular Templates Inc. Enter Into Preferred Provider Agreement For Refractory Non-Hodgkin’s B-Cell Lymphoma trial 10/13/2014 9:27:46 AM
Molecular Templates Inc. Presents Preclinical Data On CD38-Targeted Engineered Toxin Body (ETB) At The American Association For Cancer Research Special Conference, Hematologic Malignancies: Translating Discoveries To Novel Therapies 9/25/2014 2:09:42 PM
Molecular Templates Inc. Announces Completion Of $12 Million Series C Financing 9/15/2014 11:07:20 AM
Molecular Templates Inc. Templates Announces FDA Approval Of Investigational New Drug Application For CD20 Internalizing Immunotoxin MT-3724 9/8/2014 10:49:56 AM